Efficacy and effects of imatinib mesylate (Gleevec) tablets

Imatinib Mesylate, trade name "Gleevec", is a classic molecular targeted drug mainly used to treat certain types of cancer, especially chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST). As the first generation tyrosine kinase inhibitor (TKI), its advent is hailed as a milestone in the history of cancer treatment, bringing new hope to patients who previously lacked effective treatments. This article will comprehensively analyze the efficacy and role of this drug from its main indications, mechanism of action, clinical efficacy and precautions for use.

First, the main indications for imatinib mesylate include chronic myelogenous leukemia (CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), gastrointestinal stromal tumors (GIST), and other solid tumors driven by specific genetic mutations. About 95% of patients with chronic myeloid leukemia have a fusion gene called BCR-ABL, which encodes an abnormally active tyrosine kinase that drives abnormal proliferation of leukemia cells. By inhibiting the activity of this kinase, imatinib effectively prevents the growth and division of leukemia cells and fundamentally interferes with the development of the disease. In patients with GIST, the drug inhibits the proliferation of tumor cells by inhibiting KIT and PDGFRA mutated tyrosine kinases, and also significantly improves the progression-free survival of patients.

Secondly, from the perspective of its mechanism of action, imatinib mesylate is extremely targeted. It can accurately bind and inhibit the activity of BCR-ABL fusion protein and multiple abnormal kinases such as KIT and PDGFR. This precise inhibition mechanism not only improves the pertinence of treatment, but also significantly reduces damage to normal cells and reduces the systemic toxic side effects caused by traditional chemotherapy. Therefore, in many patients, imatinib can be taken long-term and maintain stable disease or even achieve molecular remission. More importantly, some CML patients can achieve "therapeutic discontinuation" after long-term use of the drug, that is, in the case of sustained deep molecular remission, they can try to stop taking the drug and continue to maintain disease control.
In clinical practice, a large amount of research data shows that imatinib mesylate has significant efficacy. For example, among patients in the chronic phase of CML, the complete cytological response rate can be as high as over 90%, and the remission at the molecular level is also very significant. Among GIST patients, the tumor stabilization rate and quality of life have been significantly improved after using this drug. Nonetheless, imatinib is not effective for all patients, and some patients may need to switch to second- or third-generation TKI drugs due to resistance or side effects. Therefore, it is necessary to regularly monitor genetic mutations, disease progression and other indicators during the treatment process to reasonably evaluate the efficacy.
Finally, you need to pay attention to some common adverse reactions when using imatinib, such as edema, rash, nausea, muscle pain, abnormal liver function, etc. Most of them are mild to moderate and reversible. In order to maximize the effectiveness of the medicine and reduce adverse reactions, patients should strictly follow the doctor's instructions and avoid increasing or decreasing the dosage or stopping the medicine without authorization. At the same time, long-term users also need to undergo regular blood routine, liver and kidney function tests, and quantitative testing of BCR-ABL fusion genes in order to evaluate drug efficacy and risk of drug resistance.
In summary, imatinib mesylate is a revolutionary targeted drug, and its application in the fields of leukemia and gastrointestinal stromal tumors has greatly improved the survival and quality of life of patients. Although a variety of new generation TKI drugs have been released, imatinib is still an important option in the treatment process for many patients, especially playing a basic and key role in the initial treatment phase. In the future, with the development of personalized treatment and precision medicine, imatinib may continue to demonstrate its clinical value in more indications and combination treatments.
Reference: https://www.gleevec.com/